Skip to main content
Figure 2 | Clinical Proteomics

Figure 2

From: Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

Figure 2

Verification of proteomics data and identification of CAPS as a potential predictive marker for early relapse of breast cancer patients receiving tamoxifen. (A) Western blot of 4 matched pairs of patients, randomly selected from the discovery set to verify CAPS and MX1 expression. (B) Relapse free survival (p = 0.049) and (C) Breast cancer survival (p = 0.11) of patients receiving adjuvant tamoxifen. Patients were divided by CAPS expression into lower tertile and 2 upper tertiles. See Table 2 for patient characteristics for (B) and (C).

Back to article page

Clinical Proteomics

ISSN: 1559-0275